Rimonabant, better known as Acomplia, is a promising new drug for weight control developed by the French pharmaceutical company Sanofi-Aventis. Acomplia offers a novel approach to appetite and weight control by blocking the endocannabinoid system, but the drug has not been approved for use in the United States.
However, the Research & Development division of Lazarus Labs has developed a non-prescription version of Acomplia that works in an almost identical fashion as the prescription drug!
INTRODUCING...ACOMPLIEX, an astounding new breakthrough formula by Lazarus Labs that is the Strongest and Most Effective appetite suppressant available today!
Acompliex works by blocking the endocannabinoid system and thus 'short circuiting' neurotransmitters in the brain that trigger cravings for food - the same basic physiological mechanism as Acomplia. This is accomplished by the dual functions of the two primary ingredients - PA (Pinolenic Acid) an exciting new discovery that has been shown to dramatically suppress appetite without causing any stimulatory effect, and Hoodia Gordonii.
Pinoleic Acid stimulates the release of the hunger-suppressing hormone CCK (cholecystokinin) and GLP1 (glucagon like peptide), which acts to slow gastic emptying and to promote a feeling of fullness and also sends a "full" feeling to the brain, decreasing the desire to eat. PA attacks the underlying mechanisms involved in hunger so effectively that participants in one study reduced their food intake by 38%!
Hoodia Gordonii works by affecting the hypothalamus, which regulates certain physiological functions and processes, including hunger. Hoodia Gordonni tricks your brain into thinking you're full.
Together, the ingredients in Acompliex delivers a potent One-Two punch to produce the Ultimate Appetite Suppressant.
If you have difficulty losing unwanted pounds and inches...
If you struggle with food cravings...
If you sometimes get hungry even though you just ate...
If you wake up in the middle of the night to raid the refrigerator...
If you'd like to start looking and feeling better NOW...
Saturday, October 25, 2008
Thursday, October 23, 2008
Acomplia
Acomplia
Acomplia (rimonabant) is an anti-obesity drug. It was approved for marketing in the European Union in June 2006. Rimonabant is not yet approved for use in the United States, where it is known as Zimulti.
What is Acomplia?
Acomplia (rimonabant) is the first in a new class of therapeutic agents called Cannabinoid-1 Receptor Blockers (CB1).
Acomplia is used in the treatment of obesity and related conditions.
How does Acomplia work?
Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle1.
Acomplia switches off the same brain circuits that make people hungry when they smoke cannabis.
CB1 receptor blockade with Acomplia acts to decrease the overactivity of the endocannabinoid system (EC system)2,3. The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism.
What is Acomplia used for?
Acomplia is used complementary to diet and exercise to treat obese or overweight patients who suffer from Type 2 diabetes and abnormal levels of fat in the blood.
Sanofi argues that Acomplia can also prevent the risk of cardiovascular disease.
Patients with large waist circumference (102 cm in men and 88 cm in women) will mostly benefit from taking the drug.
Does Acomplia also aid smoking cessation?
Acomplia has been studied by sanofi-aventis as an aid to smoking cessation based on studies for up to one year in over 6,500 smokers motivated to quit smoking.
Sanofi-aventis submitted a New Drug Application to the FDA, which in turn issued a non approvable letter for Acomplia for use in smoking cessation. An approvable letter was however issued for Acomplia for use in weight management.
Acomplia has just been approved in the European Union. Is Acomplia approved in the United States?
No. Sanofi is still awaiting U.S. marketing go-ahead which it has said could come by the end of this year.
U.S. health authorities have asked Sanofi for more information on Acomplia.
Acomplia received European Union marketing approval in June 2006.
The first launch will take place in Britain in July and be followed by launches in Denmark, Ireland, Germany, Finland and Norway in the second half of this year, according to Sanofi.
What were the results of Acomplia Clinical trial studies?
In clinical studies, Acomplia has been shown to improve a wide array of cardiometabolic risk factors as well as promoting sustained weight loss4,5.
Approximately half of the observed improvement in HDL-cholesterol, triglycerides and HbA1C (an indicator of blood sugar control) in patients who received Acomplia 20mg was beyond that expected from weight loss alone6.
What are the side-effects of Acomplia?
Side effects in the trial on Acomplia in obesity were vomiting and nausea, forcing about 19 percent of patients to leave the trial versus 13 percent of those who took placebo.
References:
Pagotto U. Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet. 2005; 365: 1363-64.
Van Gaal LF, Rissanen, AM, Scheen AJ, Ziegler O, Rössner S for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005; 365: 1389-97.
Marzo V, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410:822-825.
Després, J.P. et al. Effect of Rimonabant on Body Weight and the Metabolic Syndrome in Overweight Patients. New England Journal of Medicine, November, 16, 2005.
Van Gaal L, et al. Effects Of The Cannabinoid-1 Receptor Blocker Rimonabant On Weight Reduction And Cardiovascular Risk Factors In Overweight Patients: 1-Year Experience From The RIO-Europe Study. The Lancet. 365;1389-1397.
Acomplia Summary of Product Characteristics
Acomplia (rimonabant) is an anti-obesity drug. It was approved for marketing in the European Union in June 2006. Rimonabant is not yet approved for use in the United States, where it is known as Zimulti.
What is Acomplia?
Acomplia (rimonabant) is the first in a new class of therapeutic agents called Cannabinoid-1 Receptor Blockers (CB1).
Acomplia is used in the treatment of obesity and related conditions.
How does Acomplia work?
Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle1.
Acomplia switches off the same brain circuits that make people hungry when they smoke cannabis.
CB1 receptor blockade with Acomplia acts to decrease the overactivity of the endocannabinoid system (EC system)2,3. The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism.
What is Acomplia used for?
Acomplia is used complementary to diet and exercise to treat obese or overweight patients who suffer from Type 2 diabetes and abnormal levels of fat in the blood.
Sanofi argues that Acomplia can also prevent the risk of cardiovascular disease.
Patients with large waist circumference (102 cm in men and 88 cm in women) will mostly benefit from taking the drug.
Does Acomplia also aid smoking cessation?
Acomplia has been studied by sanofi-aventis as an aid to smoking cessation based on studies for up to one year in over 6,500 smokers motivated to quit smoking.
Sanofi-aventis submitted a New Drug Application to the FDA, which in turn issued a non approvable letter for Acomplia for use in smoking cessation. An approvable letter was however issued for Acomplia for use in weight management.
Acomplia has just been approved in the European Union. Is Acomplia approved in the United States?
No. Sanofi is still awaiting U.S. marketing go-ahead which it has said could come by the end of this year.
U.S. health authorities have asked Sanofi for more information on Acomplia.
Acomplia received European Union marketing approval in June 2006.
The first launch will take place in Britain in July and be followed by launches in Denmark, Ireland, Germany, Finland and Norway in the second half of this year, according to Sanofi.
What were the results of Acomplia Clinical trial studies?
In clinical studies, Acomplia has been shown to improve a wide array of cardiometabolic risk factors as well as promoting sustained weight loss4,5.
Approximately half of the observed improvement in HDL-cholesterol, triglycerides and HbA1C (an indicator of blood sugar control) in patients who received Acomplia 20mg was beyond that expected from weight loss alone6.
What are the side-effects of Acomplia?
Side effects in the trial on Acomplia in obesity were vomiting and nausea, forcing about 19 percent of patients to leave the trial versus 13 percent of those who took placebo.
References:
Pagotto U. Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet. 2005; 365: 1363-64.
Van Gaal LF, Rissanen, AM, Scheen AJ, Ziegler O, Rössner S for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005; 365: 1389-97.
Marzo V, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410:822-825.
Després, J.P. et al. Effect of Rimonabant on Body Weight and the Metabolic Syndrome in Overweight Patients. New England Journal of Medicine, November, 16, 2005.
Van Gaal L, et al. Effects Of The Cannabinoid-1 Receptor Blocker Rimonabant On Weight Reduction And Cardiovascular Risk Factors In Overweight Patients: 1-Year Experience From The RIO-Europe Study. The Lancet. 365;1389-1397.
Acomplia Summary of Product Characteristics
Subscribe to:
Posts (Atom)